Bromodomains: a new target class for drug development

被引：329

作者：

Cochran, Andrea G. ^{[1
]}

Conery, Andrew R. ^{[2
]}

Sims, Robert J., III ^{[2
]}

机构：

[1] Genentech Inc, Dept Early Discovery Biochem, San Francisco, CA 94080 USA

[2] Constellat Pharmaceut, Cambridge, MA 02142 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2019年 / 18卷 / 08期

关键词：

SMALL-MOLECULE INHIBITOR; INDUCED PROTEIN-DEGRADATION; STRUCTURE-BASED DESIGN; TERMINAL BET PROTEINS; E3 UBIQUITIN LIGASE; CHEMICAL PROBE; CBP/P300; BROMODOMAIN; SELECTIVE INHIBITORS; SYNTHETIC LETHALITY; BINDING-PROTEIN;

D O I：

10.1038/s41573-019-0030-7

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Less than a decade ago, it was shown that bromodomains, acetyl lysine 'reader' modules found in proteins with varied functions, were highly tractable small-molecule targets. This is an unusual property for protein-protein or protein-peptide interaction domains, and it prompted a wave of chemical probe discovery to understand the biological potential of new agents that targeted bromodomains. The original examples, inhibitors of the bromodomain and extra-terminal(BET) class of bromodomains, showed enticing anti-inflammatory and anticancer activities, and several compounds have since advanced to human clinical trials. Here, we review the current state of BET inhibitor biology in relation to clinical development, and we discuss the next wave of bromodomain inhibitors with clinical potential in oncology and non-oncology indications. The lessons learned from BET inhibitor programmes should affect efforts to develop drugs that target non-BET bromodomains and other epigenetic readers.

引用

页码：609 / 628

页数：20

共 261 条

[1]

Abramson JS, 2015, BLOOD, V126

[2] Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay [J].

Abruzzese, Maria Pia ;

Bilotta, Maria Teresa ;

Fionda, Cinzia ;

Zingoni, Alessandra ;

Soriani, Alessandra ;

Vulpis, Elisabetta ;

Borrelli, Cristiana ;

Zitti, Beatrice ;

Petrucci, Maria Teresa ;

Ricciardi, Maria Rosaria ;

Molfetta, Rosa ;

Paolini, Rossella ;

Santoni, Angela ;

Cippitelli, Marco .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9

[3]

Albrecht BK, 2016, WO Patent, Patent No. [2016/138114A1, 2016138114]

[4] TAFs revisited: more data reveal new twists and confirm old ideas [J].

Albright, SR ;

Tjian, R .

GENE, 2000, 242 (1-2) :1-13

[5] Large-scale analysis of water stability in bromodomain binding pockets with grand canonical Monte Carlo [J].

Aldeghi, Matteo ;

Ross, Gregory A. ;

Bodkin, Michael J. ;

Essex, Jonathan W. ;

Knapp, Stefan ;

Biggin, Philip C. .

COMMUNICATIONS CHEMISTRY, 2018, 1

[6] Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4 [J].

Allen, Bryce K. ;

Mehta, Saurabh ;

Ember, Stewart W. J. ;

Schonbrunn, Ernst ;

Ayad, Nagi ;

Schuerer, Stephan C. .

SCIENTIFIC REPORTS, 2015, 5

[7] Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study [J].

Amorim, Sandy ;

Stathis, Anastasios ;

Gleeson, Mary ;

Iyengar, Sunil ;

Magarotto, Valeria ;

Leleu, Xavier ;

Morschhauser, Franck ;

Karlin, Lionel ;

Broussais, Florence ;

Rezai, Keyvan ;

Herait, Patrice ;

Kahatt, Carmen ;

Lokiec, Francois ;

Salles, Gilles ;

Facon, Thierry ;

Palumbo, Antonio ;

Cunningham, David ;

Zucca, Emanuele ;

Thieblemont, Catherine .

LANCET HAEMATOLOGY, 2016, 3 (04) :E196-E204

[8] The promise and peril of chemical probes [J].

Arrowsmith, Cheryl H. ;

Audia, James E. ;

Austin, Christopher ;

Baell, Jonathan ;

Bennett, Jonathan ;

Blagg, Julian ;

Bountra, Chas ;

Brennan, Paul E. ;

Brown, Peter J. ;

Bunnage, Mark E. ;

Buser-Doepner, Carolyn ;

Campbell, Robert M. ;

Carter, Adrian J. ;

Cohen, Philip ;

Copeland, Robert A. ;

Cravatt, Ben ;

Dahlin, Jayme L. ;

Dhanak, Dashyant ;

Edwards, Aled M. ;

Frye, Stephen V. ;

Gray, Nathanael ;

Grimshaw, Charles E. ;

Hepworth, David ;

Howe, Trevor ;

Huber, Kilian V. M. ;

Jin, Jian ;

Knapp, Stefan ;

Kotz, Joanne D. ;

Kruger, Ryan G. ;

Lowe, Derek ;

Mader, Mary M. ;

Marsden, Brian ;

Mueller-Fahrnow, Anke ;

Mueller, Susanne ;

O'Hagan, Ronan C. ;

Overington, John P. ;

Owen, Dafydd R. ;

Rosenberg, Saul H. ;

Roth, Brian ;

Ross, Ruth ;

Schapira, Matthieu ;

Schreiber, Stuart L. ;

Shoichet, Brian ;

Sundstrom, Michael ;

Superti-Furga, Giulio ;

Taunton, Jack ;

Toledo-Sherman, Leticia ;

Walpole, Chris ;

Walters, Michael A. ;

Willson, Timothy M. .

NATURE CHEMICAL BIOLOGY, 2015, 11 (08) :536-541

[9] Epigenetic protein families: a new frontier for drug discovery [J].

Arrowsmith, Cheryl H. ;

Bountra, Chas ;

Fish, Paul V. ;

Lee, Kevin ;

Schapira, Matthieu .

NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (05) :384-400

[10] BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer [J].

Asangani, Irfan A. ;

Wilder-Romans, Kari ;

Dommeti, Vijaya L. ;

Krishnamurthy, Pranathi M. ;

Apel, Ingrid J. ;

Escara-Wilke, June ;

Plymate, Stephen R. ;

Navone, Nora M. ;

Wang, Shaomeng ;

Feng, Felix Y. ;

Chinnaiyan, Arul M. .

MOLECULAR CANCER RESEARCH, 2016, 14 (04) :324-331

← 1 2 3 4 5 6 7 8 9 10 →